Dr. McKay on Statin Use in Patients With mRCC

Rana R. McKay, MD, Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

In this analysis, statin users demonstrated an overall survival of 25.6 months compared with 18.9 months for non-users. This improvement was seen among patients receiving VEGF targeted therapy or mTOR targeted therapy. However, McKay says, no benefit was seen among patients receiving interferon or cytokine-based therapies.

Because of this, McKay says, statin use may be synergistic with VEGF or mTOR targeted therapies.

<<<

View more from the 2015 GU Cancer Symposium